Background: Dysbiosis of gut microbial community is associated with the pathogenesis of CD and may serve as a promising non-invasive diagnostic tool. We aimed to compare the performances of the microbial markers of different biological levels by conducting a multidimensional analysis on the microbial metagenomes of CD. Methods: We collected fecal metagenomic datasets generated from eight cohorts that altogether include 870 CD patients and 548 healthy controls. The microbial alterations in CD patients were assessed at multidimensional levels including species-, gene- and SNV- level, and then diagnostic models were constructed using artificial intelligence algorithm. Results: A total of 227 species, 1047 microbial genes and 21877 microbial SNVs were identified that differed between CD and controls. The species-, gene- and SNV- models achieved an average AUC of 0.97, 0.95 and 0.77, respectively. Notably, the gene model exhibited superior diagnostic capability, achieving average AUCs of 0.89 and 0.91 in internal and external validations, respectively. Moreover, the gene model was specific for CD against other microbiome-related diseases. Further, we found that phosphotransferase system (PTS) contributed substantially to the diagnostic capability of the gene model. The outstanding performance of PTS was mainly explained by genes celB and manY, which demonstrated high predictabilities for CD with the metagenomic datasets and was validated in an independent cohort by qRT-PCR analysis. Conclusions: Our global metagenomic analysis unravels the multidimensional alterations of the microbial communities in CD, and identifies microbial genes as robust diagnostic biomarkers across geographically and culturally distinct cohorts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.